"Single-Domain Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.
|VHH Immunoglobulin Fragments
- VHH Immunoglobulin Fragments
- Fragments, VHH Immunoglobulin
- Immunoglobulin Fragments, VHH
- VHH Fragments
- Fragments, VHH
VNAR Immunoglobulin Fragments
- VNAR Immunoglobulin Fragments
- Fragments, VNAR Immunoglobulin
- Immunoglobulin Fragments, VNAR
- VNAR Fragments
- Fragments, VNAR
Below are MeSH descriptors whose meaning is more general than "Single-Domain Antibodies".
Below are MeSH descriptors whose meaning is more specific than "Single-Domain Antibodies".
This graph shows the total number of publications written about "Single-Domain Antibodies" by people in this website by year, and whether "Single-Domain Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Single-Domain Antibodies" by people in Profiles.
Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 04 08; 137(14):1855-1861.
Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. Pediatr Blood Cancer. 2021 05; 68(5):e28949.
TTP: the evolution of clinical practice. Blood. 2021 02 11; 137(6):719-720.
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 10; 18(10):2503-2512.
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 10; 18(10):2496-2502.
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 07 04; 381(1):92-94.